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ABSTRACT
ChIP-seq performed on lymphoblastoid cell lines
(LCLs), expressing epitope-tagged EBNA3A,
EBNA3B or EBNA3C from EBV-recombinants,
revealed important principles of EBNA3 binding to
chromatin. When combined with global chromatin
looping data, EBNA3-bound loci were found to have
a singular character, each directly associating with
either EBNA3-repressed or EBNA3-activated genes,
but not with both. EBNA3A and EBNA3C showed
significant association with repressed and activated
genes. Significant direct association for EBNA3B
loci could only be shown with EBNA3B-repressed
genes. A comparison of EBNA3 binding sites with
known transcription factor binding sites in LCL
GM12878 revealed substantial co-localization of
EBNA3s with RUNX3––a protein induced by EBV
during B cell transformation. The beta-subunit of
core binding factor (CBF), that heterodimerizes
with RUNX3, could co-immunoprecipitate robustly
EBNA3B and EBNA3C, but only weakly EBNA3A.
Depletion of either RUNX3 or CBF with lentivirus-
delivered shRNA impaired epitope-tagged EBNA3B
and EBNA3C binding at multiple regulated gene
loci, indicating a requirement for CBF heterodimers
in EBNA3 recruitment during target-gene regula-
tion. ShRNA-mediated depletion of CBF in an
EBNA3C-conditional LCL confirmed the role of CBF
in the regulation of EBNA3C-induced and -repressed
genes. These results reveal an important role for
RUNX3/CBF during B cell transformation and EBV
latency that was hitherto unexplored.
INTRODUCTION
Despite being associated with various cancers––including
several B cell lymphomas––Epstein-Barr Virus (EBV) in-
fects, persistently and asymptomatically, >90% of the hu-
man population (1,2). The EBV life cycle is closely linked to
the normal B cell differentiation pathway (reviewed in 3,4).
Infection of mature B cells by EBV initially leads to their
activation and differentiation into proliferating B blasts.
Latency-associated genes expressed at this stage, termed la-
tency III, encode six EBV nuclear antigen proteins, three la-
tent membrane proteins, two small non-coding RNAs and
several microRNAs. The viral nuclear antigens expressed
include EBNA3A, EBNA3B and EBNA3C––a family of
related, but non-redundant EBV proteins, expressed from
three genes arranged in tandem within a complex transcrip-
tion unit (reviewed in 5). In vitro, infectedmature B cells give
rise to lymphoblastoid cell lines (LCLs) that carry the EBV
genome as an extra-chromosomal episome and remain in
the latency III state expressing all latency associated EBV
genes and resembling cycling, antigen-activated B blasts.
The ease of obtaining continuously proliferating LCLs from
virtually any genetic background has led to LCLs being
used in diverse studies with extensive data being generated
on genome-wide transcription factor localization, global
chromatin dynamics and analyses of the global epigenetic
landscape (see below).
In the context of viral latency, the EBNA3 family
of proteins appears to facilitate a fine balance between
activation/proliferation and protection from the oncogenic
potential this can cause (5,6). They primarily do this by con-
trolling host gene transcription. EBNA3A and EBNA3C
together specifically repress, among many other host genes,
pro-apoptotic BIM/BCL2L11 (7) and anti-proliferative
p16INK4A (8–10) two tumor suppressors that would other-
wise contribute to an oncogenic stress response resulting
from virus-induced cell activation and proliferation (6,11–
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13). In contrast, EBNA3B has been shown to act as a tumor
suppressor in a humanised-mouse model and in human tu-
mors, in part by facilitating immune cell trafficking and T
cell surveillance (14).
EBNA3 function in controlling host transcription is well
established, with more than a thousand genes probably co-
regulated (15). For each EBNA3, microarray experiments
revealed hundreds of host genes to be differentially regu-
lated when cells expressing functional or wild type EBNA3s
were comparedwith cells expressing inactivatedEBNA3s or
infected with EBNA3 knock-out virus (9,15–20).
Although they do not bind to DNA (21), the EBNA3s
robustly associate with chromatin and, by chromatin im-
munoprecipitation (ChIP), they have been found to lo-
calise at and around many EBNA3-regulated genes (exam-
ples in 19,22–26). Indeed, EBNA3 ChIP-seq experiments
have been performed previously and thousands of EBNA3
binding sites have been identified (24,27–29). These stud-
ies have been very informative, each an improvement on
the previous, as reagents and resources have become avail-
able. The current study continues this trend of optimization,
with a new recombinant virus constructed to express an N-
terminally tagged EBNA3B in an LCL and with the use of
a more appropriate background control.
The ChIP-seq data produced were analysed in combi-
nation with experimental genome-wide chromatin data,
including global chromatin looping data, available for
LCL GM12878––a ‘tier 1’ cell line of the ENCODE
project (30,31)––and microarray data identifying EBNA3-
regulated genes (9,15–20). The analysis offers new insights
into the character of EBNA3 binding sites and their rela-
tionship with EBNA3-regulated genes.
Further analysis revealed RUNX3 as the transcription
factor most significantly co-localizing with each EBNA3.
This was indicated in other studies (24,28–29), but here has
been explored in detail. RUNX3 is a member of the RUNX
family of proteins that have been found to act as oncogenes
or tumor suppressors, depending on context and cell type
(32,33). Each RUNX (RUNX1, RUNX2, RUNX3) het-
erodimerizes with core binding factor  subunit (CBF) to
form core-binding factor (CBF) (34). It is well established
that RUNX3 is an important factor during B cell devel-
opment (35–37). Here, we show that RUNX3-containing
CBF is also required for establishing stable EBNA3B and
EBNA3C complexes on chromatin and provide direct evi-
dence that this association is necessary for the regulation of
selected EBNA3C target genes.
MATERIALS AND METHODS
Production of recombinant EBV expressing TAP-tagged
EBNA3B
The FLAG-STREP II Tandem Affinity Purification (TAP)
tag (38) was fused to the N-terminus of EBNA3B in
the B95-8 EBV BAC (39). This was done using a RecA-
mediated homologous recombination system described pre-
viously (40). Briefly, the TAP-tag sequence (38) was cloned
into the pKovKanCm shuttle plasmid containing a DNA
sequence running fromwithin the end of EBNA3A through
to the end of EBNA3B exon 1, resulting in homologous re-
gions to the EBV B95-8 BAC either side of the TAP-tag in-
sert. The TAP tag was inserted in frame immediately after
the ATG start codon and is separated from EBNA3B by
the peptide linkerASNGGSGEAS.RecA-mediated homol-
ogous recombination between the shuttle plasmid and the
B95-8 BAC in DH10B Escherichia coli, using previously de-
scribedmethods (7,40), generated the required recombinant
TAP-3B BAC.
The recombinant BAC was transfected into HEK293
cells, the integrity of the EBV genome was tested by epi-
some rescue and restriction enzyme digestions analysed by
pulsed-field gel electrophoresis. Virus was produced and its
titer assessed as described previously (9).
Production of shRNA expressing lentiviruses
Double-stranded DNA for the stem sequence of each
shRNA was created by the annealing of single stranded
oligos (Supplementary Table S1) and cloned into either
pLKO.1 (Addgene plasmid #10878) or Tet-pLKO-puro
(Addgene plasmid #21915) based lentiviral plasmids (41).
After validation, 10g of each construct was co-transfected
(calcium phosphate precipitate method) with helper plas-
mids psPAX2 (8 g) and pMD2.G (2 g) into 293T cells
in 10cm culture dishes for lentivirus particle production
(seeded at 2.5 × 106 on the previous day). Virus-containing
mediumwas collected 48 h post-transfection (∼4 ml in each
case).
Viral infection of cells
Primary B cells were infected with EBV to produce LCLs as
described previously (9). For lentiviral infections of LCLs,
8 g/l polybrene was added to 20 × 106 cells in 6ml
of medium 15 min before infections. Cells were then pel-
leted by centrifugation, re-suspended in 1 ml of lentivirus-
containing 293T medium and centrifuged again at 450 g for
1.5 h at room temperature. The cells were then resuspended
in 5 ml of RPMImedium and transferred to flasks. After 48
h, further 6ml RPMI were added, containing puromycin so
that final puromycin concentration was 1 g/ml.
Cell culture and treatments
LCLs were grown at 37◦C in 10% CO2. Newly infected
cells were kept at 5% CO2 for 2 weeks. All cells were cul-
tured in RPMI-1640 medium (Invitrogen), supplemented
with 10% foetal bovine serum, penicillin and streptomycin.
Puromycin was added at 1 g/ml when selection was re-
quired. The activating ligand 4-hydroxytamoxifen (HT) was
added to 400 nM and doxycycline (DOX) to 500 ng/ml,
where indicated. These supplements were both added to cul-
tures every time fresh medium was added to the cells (three
times per week).
Immunoprecipitations, western blots and quantification of
mRNA
Co-immunoprecipitations and western blots were per-
formed as previously described (42). Supplementary Table
S2 is a list of all antibodies used in this study. RNA extrac-
tion and mRNA quantification were performed as previ-
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ously described (42). However, ALAS1 was used as an en-
dogenous control, in addition to GNB2L1, for normaliza-
tion with both giving similar results (data not shown). Se-
quences for primers used are shown in Supplementary Table
S3.
Chromatin immunoprecipitations
ChIP for factors other than the EBNA3s was performed
as described previously (42). ChIPs for the TAP-tagged
EBNA3s were done as above, but with the following modi-
fications. A suspension of 15× 106 fixed cells was made in 1
ml swelling buffer (25 M HEPES, pH 7.8; 1.5 mM MgCl2;
10 mM KCl, 0.1% NP-40; 1 mM DTT; 1 mM PMSF; 1
g/ml aprotinin; 1 g/ml pepstatin A) and incubated at
4◦C with rotation for 20 min. They were then centrifuged
at 375g for 5 min at 4◦C and the supernatant discarded.
The remaining nuclei were re-suspended in 1ml of sonica-
tion buffer (50 mM HEPES pH 7.9; 140 mM NaCl; 1mM
EDTA; 1% Triton X-100; 0.1% sodium deoxycholate; 0.1%
SDS; 1 mM PMSF; 1 g/ml aprotinin; 1 g/ml pepstatin
A) and incubated on ice for 30 min. Lysate was then soni-
cated for 1 h using a Covaris M220 Focused-ultrasonicator
with amilliTUBE holder (settings: peak power 75, duty fac-
tor 26, cycles/burst 200, set point temperature 6◦C). Soni-
cated lysate was centrifuged at 12 000g for 10 min at 4◦C
and supernatant was diluted with 3 ml of sonication buffer.
From the input sample 5% was kept at 4◦C as a control and
the rest was incubated overnight with 16 g of -FLAG an-
tibody and 120 l of ChIP-grade protein G magnetic beads
(NEB, #9006) at 4◦C in a 15 ml Falcon tube on rollers. The
following day the beads were washed with the wash buffers
described previously (42), 4 ml buffer for each wash for 15
min at 4◦C on rollers. Precipitated chromatin was eluted in
400 l of elution buffer, the eluate was treated with RNase,
formaldehyde cross-links were reversed and DNA cleaned
as described before (42), for ChIP sample and input con-
trol. Sequences for primers used to assess ChIPed DNA
are shown in Supplementary Table S3. In order to obtain
DNA for subsequent next generation sequencing, the Qia-
genMinElute PCR purification kit was used as described in
manufacturer’s instructions.
Next generation sequencing
DNA from ChIP was run on a 2% agarose gel (Bio-Rad
Low Range Ultra, #161-3107) and DNA between 100–500
bp was excised and purified using the Qiagen MinElute
gel purification kit, according to manufacturer’s instruc-
tions. At least 1 ng of DNA for each sample was then sent
to the Harvard Biopolymers facility for library construc-
tion (ChIP-Seq Wafergen) and sequencing (Illumina HiSeq
2500, 50 bp single-reads).
ChIP-Seq data analysis
Sequence reads were mapped to the human genome (vhg19)
downloaded from UCSC (43) using BWA (44). Uniquely
mapped reads obtained were 22.7 × 106 for 3A-TAP, 69
× 106 for TAP-3B, 25.7 × 106 for 3C-TAP and 34 × 106
for the non-tagged LCL. Binding regions were identified
using the MACS (45) peak-calling algorithm comparing
the sample to a control sample processed in the same way
from an LCL not expressing tagged proteins. Peaks were
defined as significant with a q value cut-off of 5.00e-02 and
are given in Supplementary File 1. Random numbers were
generated byMicrosoft Excel RANDBETWEEN function.
Peak co-localizations were determined using Partek® soft-
ware, Version 6.6 Copyright, Partek Inc., St. Louis, MO,
USA. Co-localization was defined as two peaks with one or
more base pairs in common. Publicly available peak and re-
gion tracks used are listed in Supplementary File S2 with
link addresses. RBPJ data was obtained from (46). RBPJ
peaks were called again using MACS as above for hg19, af-
ter read alignments provided were converted from hg18 to
hg19 version of the human genome using the LiftOver util-
ity on UCSC. A list of EBNA3-regulated genes considered
in this study and direction of regulation is given in Sup-
plementary File S3. Co-ordinates of genes were extracted
using UCSC Table Browser tool (https://genome.ucsc.edu/
cgi-bin/hgTables). Genes were described as within contact
domains if at least the transcription start site (TSS) was
contained within a domain. Peaks were described as be-
ing within a contact domain if at least one base pair was
shared. Pearson’s chi-squared test was performed using a
2 × 2 contingency table (47) in each case described in the
results section. The average length of contact domains not
containing regulated genes was found to be<10% different,
compared to the average length of contact domains that do
contain regulated genes, in each case (EBNA3A, EBNA3B,
EBNA3C activated or repressed genes).
RESULTS
EBNA3s associate with enhancers, regions flanking active
transcription start sites and quiescent regions of the human
genome
ChIP-seq was performed to study the localization of
EBNA3A, EBNA3B andEBNA3C across the host genome.
The LCLs used were created by infecting primary B
cells from a single donor with recombinant EBV ex-
pressing epitope-tagged EBNA3A, EBNA3B or EBNA3C.
EBNA3A and EBNA3C were tagged at the C-terminus
(22,42) with a tandem affinity purification (TAP) tag that
combines a FLAG epitope with a double Strep II epitope
(3A-TAP and 3C-TAP) (38). However, because we and oth-
ers (29,48) have found that the addition of polypeptides at
the C-terminus of EBNA3B leads to a significant decrease
in EBNA3C expression and impairment of LCL growth, we
created a recombinant EBV with the same TAP tag at the
N-terminus (TAP-3B). In TAP-3B LCLs created, EBNA3C
levels were not significantly affected, nor were the levels of
other EBV latent proteins in these cells, apart from the lev-
els of TAP-3B itself, which were slightly higher than in cells
infected with an unmodified (wild type) BAC-derived EBV
(Supplementary Figure S1A). Moreover, the cells prolifer-
ated at a similar rate to LCLs infected with the wild type,
non-tagged virus. The presence of a functional TAP tag
fused to expressed EBNA3Bwas verified by successfully im-
munoprecipitating TAP-3B with an -FLAG antibody and
detecting it with an antibody specific for EBNA3B (Supple-
mentary Figure S1B).
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For the ChIP, a commercial antibody directed against the
FLAG epitope was used. As a negative control, the same
ChIP procedure was performed on an LCL of the same ge-
netic background (i.e. same donor) infected with EBV that
does not express tagged proteins. Pooled ChIP DNA from
eight (3C-TAP, TAP-3B) or 12 (3A-TAP and non-tagged)
precipitation experiments was then tested by QPCR to ver-
ify that there was significant enrichment at known targets of
EBNA3A, EBNA3B and EBNA3C that could be detected
in the material from tagged cell lines relative to the non-
tagged LCL (Figure 1A). The ChIP DNA was then sub-
jected to next generation sequencing and reads produced
were aligned to version hg19 of the human genome (Fig-
ure 1B for examples). EBNA3 peaks were called for each of
the three proteins by using the reads obtained from the non-
tagged LCL as background control (Figure 1C and Supple-
mentary Figure S2 for examples). After alignment of the
sequenced reads, the MACS algorithm was used to iden-
tify peaks. Specifically for EBNA3B using the algorithm
was used with the broad peak setting because there were 64
peaks called with the broad peak setting, that were not rec-
ognized without this setting (49). The same trends were not
observed for EBNA3A and EBNA3C. However, using the
broad peak setting, a number of peaks that were close to-
gether were recognized as a single peak and these were then
manually delineated (23 peaks––Supplementary File S1).
Applying the MACS algorithm, 1715 peaks were identi-
fied for EBNA3A, 454 for EBNA3B and 3835 for EBNA3C
(Figure 2A). There is a significant co-localization between
EBNA3A and EBNA3C (1429 peaks co-localized) and be-
tween EBNA3B and EBNA3C (301 peaks co-localized).
However, EBNA3A and EBNA3Bwere almost never found
together without EBNA3C also being present (only three
peaks co-localized––Figure 2A). This indicates a different
mode of recruitment for EBNA3A and EBNA3B or inabil-
ity of one to recruit the other in the absence of EBNA3C.
Extensive ChIP-seq data are available from the EN-
CODE project for an LCL, GM12878 [https://www.
encodeproject.org/ (30)], including data for several histone
modifications. These data (Supplementary File S2) were
used to determine the association of each EBNA3 with re-
gions rich in specific histone modifications. We, like oth-
ers (27–29), have found that all three EBNA3s largely
co-localize with histone modifications associated with ac-
tive enhancers––identified by H3K27ac and H3K4me1 and
with promoters of actively transcribed genes––identified
by H3K4me2, H3K4me3, H3K27ac, H3K9ac and histone
variant H2A.Z (50) (Figure 2B). When we compared, here
for the first time, all EBNA3 peaks with peaks where only
a single EBNA3 was present, for EBNA3A and EBNA3C
we saw that the trends for histone mark association were
very similar (Figure 2B). However, EBNA3B-only peaks
have a broader distribution, including histonemarks associ-
ated with gene bodies, such as H4K20me1 (51), H3K36me3
and H3K79me2 (52) (Figure 2B). The most remarkable dif-
ference between EBNA3B-only and total EBNA3B peaks
was the greater association of EBNA3B-only peaks with
H3K36me3, a histone mark linked with exonic regions
(52,53) (Figure 2B).
We next took advantage of the data from the Roadmap
Epigenomics Consortium (54) (Supplementary File S2).
These include the segmentation of the genome for dif-
ferent cell types, according to chromatin state, as deter-
mined by different histone marks, DNA methylation and
DNA accessibility. A 15-state model was created by the
Consortium,assigning genomic regions to one of eight ac-
tive or seven repressed states. The cell types included LCL
GM12878 and CD19-positive primary B cells from periph-
eral blood––the cell type we used to create LCLs by in-
fection with EBV. When the peaks for each EBNA3 were
aligned to the chromatin states for an LCL, unsurprisingly
the great majority were found at regions classed as en-
hancers and at––or near––active transcription start sites
(TSS), with a minority at regions of quiescent chromatin
(Figure 2C). EBNA3B-only peaks have a distinctly differ-
ent distribution, with markedly less at enhancers and TSS
than the other categories of peaks and more at quiescent
regions and at regions of active transcription. Aligning the
same peaks to chromatin states from primary B cells re-
vealed that many regions of EBNA3 peaks in LCLs classed
as active TSS, were classed as quiescent in primary B cells
(Figure 2C). This suggests that many quiescent TSS in non-
infected primary B cells become active following infection
and targeting by the EBNA3s.
Global chromatin looping data reveals direct and indirect reg-
ulation by EBNA3s
To relate the peaks identified by our ChIP-seq with
EBNA3-regulated genes revealed by microarrays from
LCLs (10,15,17) data from a study revealing global chro-
matin looping in an LCL (31) were used. The outputs of
this study included the partitioning of the LCL genome
into contact domains––regions with significant long-range
associations within them, suggesting chromatin looping.
The median length of the contact domains was 185 kb
(see Figure 3A for example). We identified contact domains
that contain known EBNA3-regulated genes and ChIP-seq
peaks thus linking genes with peaks that are not necessarily
close, but for which there is evidence of association by chro-
matin looping. EBNA3 up-regulated and down-regulated
genes were considered separately, 365 genes for EBNA3A,
420 genes for EBNA3B and 427 genes for EBNA3C (Fig-
ure 3B). These genes were all found in contact domains
and were differentially expressed by at least 2-fold and/or
with P≤ 0.001, between LCLs expressing or not expressing
the relevant active EBNA3 (10,15,17; http://www.epstein-
barrvirus.org.uk/).
The percentage of contact domains that contain EBNA3
peaks and also the relevant regulated genes was calculated
(Figure 3C). This was found to be significantly higher than
the percentage of contact domains that contain EBNA3
peaks, but do not contain up- or down-regulated genes for
each EBNA3, in all cases apart from the case of EBNA3B-
up-regulated genes (Figure 3C). This implies that there is
a specific enrichment of peaks at domains with regulated
genes, apart from domains with EBNA3B-activated genes.
To further assess the significance in the associations de-
tected, random ‘peaks’ were generated for each EBNA3.
These were a list of genomic locations––the same in num-
ber as the real peaks, with the same lengths as the real peaks,
but with their locations determined randomly. The percent-
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Figure 1. ChIP-seq design and quantification of EBNA3 binding sites on the human genome. (A) Multiple ChIP experiments were performed, using an
-FLAG antibody to precipitate EBNA3A- and EBNA3C-tagged with a tandem array purification (TAP) tag at the C-terminus or to precipitate EBNA3B
with the same tag fused at the N-terminus (TAP-3B). LCLs expressed each of these proteins from BAC-derived EBV recombinants. For a background
control, the same ChIP was performed in an LCL infected with a wild type virus, not expressing tagged proteins. Multiple ChIPed DNA samples from
each cell line were pooled and assayed by QPCR for enrichment, relative to input, at known EBNA3 target sites on the genome (17,19,27). The Myoglobin
gene promoter region was used as a negative control. Histogram bar heights represent enrichment over percentage of input stated; error bars represent
standard deviation between triplicate QPCR runs. (B) ChIPed DNA was subjected to next generation sequencing and reads produced were mapped to the
human genome (version hg19) using the BWA algorithm (44). (C) Using the aligned reads produced from ChIP in non-tagged LCL, 3A-TAP, TAP-3B and
3C-TAP peaks were called using the MACS algorithm (45).
age of contact domains with EBNA3-regulated genes that
also contain real peaks is considerably higher than for the
same domains also containing randomly permuted ‘peaks’,
in every case, apart from domains containing EBNA3B
up-regulated genes (Supplementary Figure S3). Therefore,
there is a positive enrichment for real peaks associated with
EBNA3-regulated genes, apart fromEBNA3Bup-regulated
genes. The random ‘peaks’ established a baseline: the num-
ber of regulated gene-containing domains found by chance
by the EBNA3 peaks. This was in all cases remarkably sim-
ilar to the percentages of domains without regulated genes
that associated with real peaks (compare Figure 3C to Sup-
plementary Figure S3). That is, real peaks behave like ran-
dom peaks for domains without EBNA3-regulated genes,
indicating that the peaks we identified do not regulate a
significant number of additional genes we are not consid-
ering. Surprisingly, EBNA3B is probably activating genes
indirectly, since no significant direct association between
EBNA3B peaks and EBNA3B up-regulated genes could be
found.
Contact domains that include EBNA3-regulated genes are ei-
ther activated or repressed, but not both
There are contact domains that contain more than one
EBNA3-regulated gene. For each EBNA3, all such domains
were identified, as was the direction of regulation for each
EBNA3-regulated gene within them (Table 1). Remarkably,
for every one of those domains, all the EBNA3-regulated
genes within a single domain were regulated in the same di-
rection (activated or repressed). The only exception is one
domain that contains EBNA3B up- and down-regulated
genes––but since we determined that EBNA3B is probably
only a repressor, the up-regulated genes within that single
domain are likely to be regulated indirectly. This conclusion
is further supported by the observation that there are no
other contact domains containing more than one EBNA3B
up-regulated gene, whereas there are 14 contact domains
that contain multiple EBNA3B down-regulated genes (Ta-
ble 1). For both EBNA3A and EBNA3C there are very sim-
ilar numbers of contact domains containing either activated
or repressed genes (Table 1).
EBNA3s co-localize with similar transcription factors
Extensive ChIP-seq data are available for the localization
of cell transcription factors in LCL GM12878. Data from
90 different ChIP-seq experiments for transcription factor
localization, uniformly analysed and available from the EN-
CODE project (29, Supplementary File S1) were used to
assess co-localization with each of the EBNA3s. ChIP-seq
data for transcription factor RBPJ from a separate study
(46) was also used (this was performed using the LCL IB4
that expresses no EBNA3B). The total number of peaks
for each EBNA3 was considered and the 20 transcription
factors most frequently co-localizing with each are shown
(Figure 4). EBNA3A-only, EBNA3B-only and EBNA3C-
only peaks were also compared to the same transcrip-
tion factor binding sites (Figure 4). Co-localization with
cell transcription factors is remarkably similar between the
EBNA3s, with the majority of the top 20 factors common
to all three (Figure 4). When considering co-localizations
of EBNA3A or EBNA3C peaks with transcription factors
in domains with up-regulated or down-regulated genes sep-
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Figure 2. Co-localization of EBNA3A, EBNA3B and EBNA3C peaks and their association with enhancer elements and regions flanking active TSS. (A)
Total numbers of peaks for eachEBNA3, as determined by theMACSalgorithm, and the degree towhich they co-localize. Peakswere classed as co-localized
if they had one or more bp in common. (B) Co-localization with histone modification marks of LCL GM12878 from the ENCODE project. Total peaks
for each EBNA3 and regions with only one EBNA3 (EBNA3A-, EBNA3B- or EBNA3C-only) considered separately. The length of each histogram bar
represents the percentage of peaks co-localizing with each histone modification. Many peaks co-localize with more than one histone modification mark
because many regions include more than one modification. (C) Co-localization of EBNA3 peaks with genome segments corresponding to 15 different
chromatin states that have been characterized as part of the ENCODE project. Peaks found by ChIP-seq in LCL where aligned to chromatin states in LCL
and CD19+ve 1◦ B cells. Total peaks and ‘only’ peaks for each EBNA3 were considered separately.
arately, the same frequencies are retained (not shown) and
therefore, these transcription factors could not be specifi-
cally correlated with either activation or repression. Con-
sidering EBNA3B-only peaks separately, it might be signif-
icant that the factor seventh most frequently co-localized
is RNA polymerase II [(POLR2A), Supplementary Figure
S4)], which is not in the top 20 of the other EBNA3s, re-
flecting the association of EBNA3B-only peaks with tran-
scribed regions. It should also be noted that co-localization
of EBNA3B-only peaks with the transcription factors con-
sidered is low, with the top factor only co-localizing with
25% of EBNA3B-only peaks (Figure 4 and Supplementary
Figure S4). However, the most frequently co-localized fac-
tor with EBNA3B-only peaks is still RUNX3, which is also
most frequently co-localized with EBNA3A-only and all
EBNA3C peaks (Figure 4).
EBNA3B and EBNA3C each co-immunoprecipitate with
CBF, the partner of RUNX3 in Core Binding Factor (CBF)
Expression of RUNX3 is induced during the infection of
B cells, because the gene encoding this transcription factor
is a direct target of the EBV transactivator EBNA2 (55–
57). With this in mind––and because RUNX3 extensively
co-localizes with EBNA3s on chromatin across the human
genome––wewanted to explorewhether any of the EBNA3s
can be found in complexes with RUNX3. An anti-RUNX3
antibody was used to immunoprecipitate RUNX3 from ex-
tracts from LCLs infected with wild type EBV. However,
after repeated attempts no EBNA3s were reproducibly or
convincingly co-immunoprecipitated with RUNX3 (Figure
5A).
As mentioned before, RUNX proteins bind to DNA
as a heterodimer with CBF and together they form
core-binding factor (CBF). Consequently, an anti-CBF
antibody was used to immunoprecipitate CBF from
LCL protein extracts and, as expected, RUNX3 co-
immunoprecipitatedwithCBF (not shown). EBNA3A co-
immunoprecipitated very weakly with CBF, but EBNA3C
and EBNA3B did so significantly––the latter most ro-
bustly (Figure 5B). EBNA2, although it can sometimes
co-localize with the EBNA3s on chromatin (27,29), did
not co-immunoprecipitate with CBF under the same con-
ditions (Figure 5B). Similar immunoprecipitation exper-
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Figure 3. Assessment of direct and indirect regulation by EBNA3s by combining microarray, ChIP-seq and Hi-C data. (A) Schematic from the UCSC
genome browser with the EBNA3C peaks, random peaks and contact domains tracks for illustration. The contact domain at the centre contains two
EBNA3C down-regulated genes––DDX6 and CXCR5. It also contains other genes that show no evidence of EBNA3 regulation. (B) Numbers of the most
robustly EBNA3-regulated genes, as determined by previous microarray transcriptome studies, divided into down- (repressed) and up-regulated (activated)
genes. (C) In light gray histogrambars, the percentages of contact domains containing regulated genes also containing the relevant EBNA3peaks are shown.
The black bars represent the percentages of contact domains not containing the relevant EBNA3-regulated genes (up- or down-regulated), but containing
EBNA3 peaks. Pearson’s chi-squared test was performed to assess the difference in co-localization of peaks with contact domains, either containing or not
containing relevant regulated genes. (*) denotes P < 0.05 of difference occurring by chance.
iments were performed in LCLs infected with a recom-
binant EBNA3C- or EBNA3B-knock-out virus (10,15))
and showed that EBNA3B and EBNA3C can be co-
immunoprecipitated with CBF independently of each
other and that EBNA3A co-immunoprecipitates in the ab-
sence of its main co-localizing EBNA3, EBNA3C (Supple-
mentary Figure S5).
Depletion of RUNX3 or CBF reduces recruitment of
EBNA3s to EBNA3-regulated gene loci
Since the EBNA3s all appear in complexes with CBF,
lentiviruses that express shRNAs targeting RUNX3 and
CBF were constructed to assess the role of these fac-
tors in EBNA3 recruitment to chromatin. Two indepen-
dent lentiviruses expressing different shRNAs were pro-
duced for each mRNA and these depleted the target pro-
teins to a similar extent in three independent experiments,
however here only one of each is shown (Figure 6A). All
the lentiviruses also expressed the gene for puromycin resis-
tance. RUNX3 and CBF expression was knocked down
in the LCLs that express the tagged versions of EBNA3A,
EBNA3B or EBNA3C. Puromycin was added 2 days after
lentiviral infection and the cells were harvested after a fur-
ther 4 days. Depletion of both factors was efficient, when
compared to the same lines infected with lentiviruses ex-
pressing a non-targeting shRNA (Figure 6A). The levels of
each tagged EBNA3 were unaffected by the knock-downs,
but in the cells with CBF depleted, the level of RUNX3
protein was also reduced (Figure 6A). This was consistent
with reports that CBF stabilizes RUNX proteins (58). The
level of IRF4 in the cells did not change with RUNX3 and
CBF depletion (Figure 6A). IRF4 was tested because it
was previously shown to play a role in EBNA3C targeting
(24,29,59).
Anti-FLAG ChIPs were performed on these cells, fol-
lowed by Q-PCR to assess the levels of EBNA3-TAP bound
at EBNA3peaks associatedwith selectedEBNA3-regulated
genes (Figure 6B-H). Enrichment was determined relative
to input for cells that had RUNX3 or CBF knocked down
or cells infected with the non-targeting control lentivirus.
Reduced levels of each EBNA3 were seen at loci associ-
ated with EBNA3-regulated genes (Figure 6B–H), indicat-
ing that CBF is important for EBNA3 recruitment to chro-
matin.
A lentivirus expressing shRNA for IRF4 was also pro-
duced, in order to assess the role of this factor in a simi-
lar experiment. IRF4 was only knocked down in the 3C-
TAP cell line (Supplementary Figure S6A), because it was
found previously to direct only EBNA3C recruitment (29).
Reduced binding of 3C-TAP around EBNA3C-regulated
genes was seen after IRF4 depletion (Supplementary Fig-
ure S6B), confirming the role for IRF4 in recruitment, as
has been previously suggested (24,29).
As a control for RUNX3, CBF and IRF4 depletion
experiments, EBNA2 ChIPs were performed in a similar
manner, on the same batch of chromatin, after their infec-
tion with each shRNA-expressing lentivirus to show that
the trend of reduced EBNA3 enrichment after knock-down
was specific. EBNA2 enrichment at known EBNA2 peaks
was not diminished after knockdown of any of these tran-
scription factors and in most cases more EBNA2 was ob-
served (Supplementary Figure S6C), most likely due to the
antagonistic relationship of EBNA3 and EBNA2 recruit-
ment shown previously (60–63).
For EBNA3B, a site where no RUNX3 binds was used as
a control to show that diminished binding was only found at
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Table 1. Contact domains containing more than one EBNA3-regulated gene
ZCCHC11 DOWN chr1: 52870001-
53160000GPX7 DOWN
MAP4K4 DOWN
chr2: 102495002-
103085000IL1R2 DOWN
IL18R1 DOWN
SCHIP1 UP chr3: 159545003-
160115000IQCJ-SCHIP1 UP
CXCL10 DOWN
chr4: 76815001-
77065000NAAA DOWN
CXCL9 DOWN
HECA DOWN chr6: 138900005-
139695000CITED2 DOWN
GIMAP4 DOWN
chr7: 150150001-
150460000GIMAP6 DOWN
GIMAP5 DOWN
ADAMDEC1 DOWN chr8: 24095004-
24290000ADAM28 DOWN
EPB41L4B DOWN chr9: 111610001-
112290000PTPN3 DOWN
TMX2-CTNND1 UP chr11: 57090002-
57590000CTNND1 UP
BIRC3 UP chr11: 102150001-
102495000MMP7 UP
RP11-172E9.2 DOWN chr13: 40510001-
41345000FOXO1 DOWN
RB1 UP
chr13: 48670003-
49350000LPAR6 UP
RCBTB2 UP
CCL5 UP
chr17: 34165004-
34490000CCL3 UP
CCL4 UP
SYS1-DBNDD2 UP chr20: 43940004-
44090000DBNDD2 UP
CASP8 DOWN chr2: 202100001-
202250000
STRADB DOWN
LINC00888 DOWN chr3: 183155001-
183535000
KLHL6 DOWN
GPM6A DOWN chr4: 176855001-
177275000
WDR17 DOWN
HSPA1B DOWN
chr6: 31460004-
31940000
MCCD1 UP
HSPA1A DOWN
TNF UP
RP11-13P5.1 DOWN chr6: 159420001-
159565000
TAGAP DOWN
TNFRSF10A DOWN chr8: 22920003-
23290000
TNFRSF10D DOWN
AC051642.1 DOWN
chr8: 23315002-
23580000NKX3-1 DOWN
FP15737 DOWN
PRKCQ-AS1 DOWN chr10: 6460005-
6730000
PRKCQ DOWN
HHEX DOWN chr10: 94355001-
94620000
EXOC6 DOWN
BAG3 DOWN chr10: 121420002-
121650000
INPP5F DOWN
FLOT2 DOWN chr17: 27050001-
27275000
DHRS13 DOWN
LILRA4 DOWN chr19: 54835001-
54920000
LAIR1 DOWN
AF165138.7 DOWN chr21: 15895001-
16060000
AF127936.3 DOWN
MICAL3 DOWN chr22: 18560001-
18660000
XXbac-B461K10.4 DOWN
CLCN4 DOWN chrX: 9965001-
10090000
WWC3 DOWN
PTAFR UP
chr1: 28150002-
28570000EYA3 UP
ATPIF1 UP
VASH2 UP chr1: 212635005-
213250000BATF3 UP
HNRNPA1P21 DOWN chr3: 39095005-
39450000CCR8 DOWN
CD86 UP chr3: 121715001-
121820000ILDR1 UP
NCR3 UP
chr6: 31460004-
31940000HSPA1A UP
TNF UP
SESN1 DOWN chr6: 108850002-
109410000FOXO3 DOWN
ADAM28 DOWN
chr8: 24095004-
24290000RP11-624C23.1 DOWN
ADAMDEC1 DOWN
CXCR5 DOWN chr11: 118535002-
118850000
DDX6 DOWN
PCED1B UP chr12: 47575001-
47705000PCED1B-AS1 UP
MYO1E UP chr15: 59815001-
59980000FAM81A UP
ZSCAN2 DOWN
chr15: 85120004-
85350000WDR73 DOWN
NMB DOWN
VEZF1 UP chr17: 55925001-
56080000CUEDC1 UP
DSC1 DOWN chr18: 28565003-
29000000DSG1 DOWN
MBD1 UP chr18: 47795001-
47900000CXXC1 UP
MYBL2 UP chr20: 42730001-
42835000TOX2 UP
ABCG1 UP chr21: 43555003-
43970000SLC37A1 UP
APOL6 UP chr22: 36535001-
36685000HMOX1 UP
EBNA3A regulated genes EBNA3B regulated genes EBNA3C regulated genes
The EBNA3-regulated genes within them, the direction of regulation for each gene and the genomic coordinates of each contact domain are shown.
CBF sites, after depletion of either RUNX3 or CBF (Sup-
plementary Figure S6D).Wewere unable to find––byChIP-
QPCR––EBNA3A or EBNA3C peaks where CBF binding
was not above background (data not shown).
EBNA3C stabilizes CBF on chromatin
Although we found that efficient localization of EBNA3B,
EBNA3C and to a lesser extent EBNA3A is dependent on
the presence of CBF, it was unknown how the EBNA3s
affect the occupancy of CBF at the same loci. In order
to assess this, we used two LCLs expressing either a con-
ditional EBNA3C or a conditional EBNA3A. The use of
conditional EBNA3s, allowed us to detect changes soon
after expression of active EBNA3s, avoiding the problems
of a long LCL outgrowth process that is subject to selec-
tion pressures. The conditional EBNA3C LCL is p16INK4A-
null and expresses EBNA3C fused to a modified estro-
gen receptor (3CHT) that renders 3CHT active only in
the presence of 4-hydroxytamoxifen (HT) (10). In the ab-
sence of HT, 3CHT is sequestered to the cytoplasm, where
it is degraded. This LCL was established after infection
with EBV without ever being treated with HT––i.e. with-
out ever expressing functional EBNA3C (3CHT never HT).
This is possible because the cells lack p16INK4A, which
would otherwise be induced and arrest cells not express-
ing EBNA3C (10). The conditional EBNA3A LCL ex-
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Figure 4. Co-localization of EBNA3 peaks with transcription factors reveals striking similarities between EBNA3s. Total numbers of peaks for each
EBNA3 and regions with only one EBNA3 (EBNA3A-, EBNA3B- or EBNA3C-only) were considered separately. The height of histogram bars represents
the percentage of peaks that co-localize with each transcription factor binding site (TFBS). The 20 factors most commonly co-localized with the total
number of binding peaks for each EBNA3 are shown. Black dots above bars indicate factors that are in the top 20 for all 3 EBNA3s. For transcription
factors appearing more than once, more than one track from independent experiments were available from ENCODE.
presses EBNA3A fused to a newer version of the estro-
gen receptor than the one used for EBNA3C, termed ERT2
(3AERT2) (22,64), and it was also grown out without ever
being treated with HT––without ever expressing functional
3AERT2.Unfortunately, attempts to produce a similar con-
ditional EBNA3B-expressing recombinant virus were un-
successful because of technical problems associated with ex-
tending the EBNA3B open reading frame.
Cultures of 3CHT or 3AERT2 LCL never exposed to
HT were split and to one half of each HT was added for 5
days. Cells with and without HT were harvested for protein
and RNA extraction or fixed for ChIP. The time course for
3CHT was repeated three times and 3AERT2 twice. Stabi-
lization of 3CHT and 3AERT2 was verified byWestern blot
(Figure 7A). The ability in these LCLs to regulate mRNA
abundance of known EBNA3A or EBNA3C target genes
was confirmed by RT-QPCR (Figure 7B and C), demon-
strating the functionality of 3CHT and 3AERT2 during the
5 days of the time course. ChIPs for CBF and RUNX3
were performed and the enrichment of both was assessed
by QPCR (Figure 7D and E). The loci tested contained
peaks of RUNX3 (as determined by data available from
ENCODE) and EBNA3, or––as controls––loci where there
is no evidence of EBNA3 binding (Figure 7D and E). These
control loci contained RUNX3 and/or IRF4, or, in the case
of myoglobin, did not contain peaks for any of the factors
studied. As an additional control, ChIP for EBNA2 was
performed at the same time, to show that the trends ob-
served for the factors studied were specific (Supplementary
Figure S7).
When HT was added to the LCL 3CHT cells never ex-
posed toHT, occupancy of bothCBF andRUNX3was in-
creased at loci where EBNA3was found, but not at loci with
no EBNA3 binding (Figure 7D). Activation of 3AERT2 by
the addition of HT did not have this effect––no apprecia-
ble increase in either CBF or RUNX3 occupancy being
observed at any of the chosen target loci (Figure 7E). This
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Figure 5. EBNA3B and EBNA3C co-immunoprecipitate with CBF in
WT LCL. (A) RUNX3 was immunoprecipitated using a rabbit anti-
RUNX3 antibody and the precipitate was separated by SDS-PAGE and
probed by western blotting for EBNA3A, EBNA3B, EBNA3C or, as a
positive control, RUNX3, using non-rabbit antibodies; 10% of input sam-
ple is shown for comparison. A rabbit anti-FLAG antibody was used for
the same non-tagged cell line lysate as negative control (-ve: FLAG). (B)
CBF was immunoprecipitated using a rabbit anti-CBF antibody. The
precipitate was separated by SDS-PAGE and probed by western blotting
for EBNA3A, EBNA3B, EBNA3C, CBF or EBNA2; 10% of the input
sample is shown for comparison and for negative control an anti-FLAG
immunoprecipitation was used as in (A).
indicates that EBNA3C, but not EBNA3A, stabilizes CBF
at loci of EBNA3 binding.
CBF is required for efficient regulation of target genes by
EBNA3C
EBNA3C was shown to co-immunoprecipitate with CBF
fromwhole cell extracts, CBFwas found to be required for
efficient EBNA3C localization to chromatin and EBNA3C
was shown to stabilize CBF on chromatin. We therefore
wanted to determine whether CBF was also important for
EBNA3C to act as a regulator of host genes. For this the
pLKO-Tet-On lentiviral system for doxycycline (DOX) in-
ducible knock-down of CBF was used (65) (Figure 8A).
Two independent lentiviruses were produced with different
shRNAs targeting CBF (Supplementary Table S1) and the
experiment was performed twice for each lentivirus, show-
ing similar results. DOXwas added to 3CHTLCL never ex-
posed toHT cells that were also infected with this lentivirus,
in order to knock down CBF. After 3 days, HT was also
added to activate 3CHT (Figure 8B). Fourteen days after
activation of 3CHT (by addition of HT)––and 17 days af-
ter knocking down CBF (by the addition of DOX), cells
were harvested for protein and RNA (Figure 8B). Addi-
tion of DOX induced a robust reduction in CBF protein
levels, assessed by western blot, irrespective of the pres-
ence of active 3CHT (Figure 8C). Similarly, 3CHT sta-
bilization was assessed, as was the stability of EBNA3A
and EBNA3B throughout the time course (Figure 8C). The
levels of mRNA were determined by RT-QPCR for sev-
eral genes known to be either up-regulated (Figure 8D)
or down-regulated (Figure 8E) by EBNA3C. Relative to
cells that had never expressed active 3CHT, activation of
EBNA3C-regulated geneswas significantly less pronounced
when CBF was depleted (Figure 8D). Concurrently, im-
paired repression of EBNA3C-down-regulated genes was
also seen when CBF was depleted (Figure 8E). Together
these data unequivocally establish that CBF is necessary for
the regulation of host genes by EBNA3C.
DISCUSSION
In this study, we performed ChIP-seq to assess genome-
wide localization of EBNA3A, EBNA3B and EBNA3C.
Similar studies have revealed many aspects of the binding-
site characteristics and of EBNA3 function (24,27–29).
Here, an experimental protocol that significantly improves
on previous studies was used. We were able to ChIP each
of the three EBNA3s, using the same antibody––since they
were all tagged with the same tandem affinity purification
tag––in the same genetic background and with cells prolif-
erating equally well in all instances. This is the first time this
has been achieved. Additionally, ChIP DNA from a LCL
infected with wild type EBV expressing non-tagged proteins
provided a more refined control for DNA accessibility and
sequencing bias as well as for non-specific antibody bind-
ing. Finally, for peak calling we used the MACS algorithm
(45), which is also used by ENCODE (30) in their uniform
peak calling pipeline.
Comparing the EBNA3 MACS peaks called, we see
that in general there is significant co-localization between
EBNA3C and EBNA3A (83% of -3A co-localized) and be-
tween EBNA3C and EBNA3B (66% of -3B co-localized),
but it appears that any co-localization between EBNA3A
and EBNA3B occurs in the presence of EBNA3C, with
only three regions of EBNA3A-EBNA3B exclusive co-
localization (Figure 2). The epigenetic landscape at regions
of EBNA3 peaks and the chromatin state derived from
this landscape are very similar between EBNA3s, with a
strong association with enhancer and TSS regions (Fig-
ure 2B and C). However, the decision to consider sepa-
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Figure 6. Depletion of RUNX3 and CBF disrupts recruitment of EBNA3A, EBNA3B and EBNA3C in the regions of robustly regulated genes. (A)
EBNA3A-TAP, TAP-EBNA3B-and EBNA3C-TAP tagged expressing LCLs were infected with lentiviruses producing shRNAs that targeted RUNX3
(shRUNX3), CBF (shCBF) as indicated or producing a control, non-targeting shRNA (shNT) and cells were harvested 6 days after infection with
lentivirus. Depletion of RUNX3 and CBF was confirmed, and the expression of each EBNA3 and also IRF4 were demonstrated by western blotting. (B-
I) ChIP analyses using an anti-FLAG antibody in 3A-TAP, TAP-3B and 3C-TAP cell lines with knock-downs as indicated. Histogram bar heights represent
fold-enrichment relative to 5% input sample and standard deviations are calculated from QPCR triplicates for each sample. RUNX3 and CBF knock-
downs have been performed independently with two different shRNAs each, with similar results. Representative examples from the best knock-downs are
shown. Primers amplifying a region of the Myoglobin promoter were used as negative control.
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Figure 7. EBNA3Cbut not EBNA3A stabilizes CBF andRUNX3on chromatin. LCLs carrying either a conditional EBNA3A (3AERT2) or a conditional
EBNA3C (3CHT) that are activated by addition of HT to the culture medium were used. Both cell lines were produced with no HT present in the medium
from when 1◦ B cells were infected (Never). HT was added to half the culture to activate either EBNA3A or EBNA3C and cells were harvested after 5
days. (A) Activation and stabilization of 3AERT2 and 3CHT proteins was shown by western blotting. No change in levels of EBNA3B, CBF, RUNX3
and IRF4 after activation was detected. (B) RT-QPCR for mRNA levels of robustly EBNA3C-regulated gene COBLL1 after 5-day activation of 3CHT
with addition of HT. (C) RT-QPCR for mRNA levels of EBNA3A-regulated gene STK39, following 5-day activation of 3AERT2 with addition of HT.
(D) ChIP for CBF and RUNX3 carried out for Never HT and 5 days HT 3CHT cultures. Enrichment at several EBNA3-regulated genes was assessed.
Enrichment at control loci where there was no apparent EBNA3 binding was also assessed. A locus at the promoter region of the Myoglobin gene acts as
a control for no enrichment for any of these factors. (E) As in (D), but for 3AERT2. For all QPCR, error bars represent standard deviations calculated
from triplicates for each sample.
rately peaks with only one EBNA3 present revealed that
EBNA3B-only peaks are qualitatively different, showing
preference for chromatin characteristic of gene bodies and
exonic regions in particular (Figure 2B and C). The signifi-
cance of this has not yet been determined, but the majority
(87%; data not shown) of EBNA3B repressed genes do not
have EBNA3B peaks within their bodies, suggesting that
the peaks within gene bodies are distally targeted and sub-
ject to chromatin looping, rather than directly repressing the
genes in which they are found.
Another striking observation concerning EBNA3 peaks
was revealed by examining the same loci, but in uninfected
primary B cells (Figure 2C). For all EBNA3s, a significant
proportion of peak regions lie close to TSS determined to be
quiescent in primary B cells. However, there is no evidence
that a significant number of these TSS belong to EBNA3
activated genes, with no more than 10% (data not shown)
for any EBNA3. The change in chromatin character prob-
ably facilitates EBNA3 targeting, but it does not necessar-
ily seem to be caused by the EBNA3s, because in that case
these genes would have been identified as EBNA3-activated
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Figure 8. CBF is required for efficient gene regulation by EBNA3C. (A) The 3CHT LCL never exposed to HT was used, which expresses a conditional
EBNA3C (3CHT––active only after addition of HT). Inducible shRNA targeting mRNA of the CBF subunit CBF was used (pLKO-Tet-On). This was
generated from a lentiviral construct that constitutively expresses the tetracyclin repressor (TetR). The shRNA can be expressed from an H1 promoter
upstream of two Tet Response Elements (TRE). In the absence of the tetracycline analogue doxycycline (DOX), transcription is prevented allosterically
by binding of TetR to TRE. Addition of DOX changes the conformation of TetR, which can no longer bind TRE and transcription of the shRNA is
possible. After processing, the shRNAmediates knock-down of CBF which is no longer available to 3CHT, activated after addition of HT. (B) Schematic
of the time course experiment: DOX was added to half the culture of the 3CHT LCL (never HT) carrying pLKO-Tet-On to induce expression of shRNA
against CBF, resulting in two cultures as shown. After 3 days HT was added to half of each culture to activate 3CHT, resulting in the four cultures shown.
After 14 days of HT, cells were harvested. (C) Western blots of extracts from all 4 resultant cultures, showing efficient knock-down of CBF after addition
of DOX, stabilization of 3CHT after addition of HT and levels of EBNA3A and EBNA3B proteins. Gamma-tubulin was used as a loading control. (D)
RT-QPCR of extracted RNA; mRNA levels of EBNA3C up-regulated genes (AICDA and IL6R) after activation of 3CHT, relative to their levels before
activation of 3CHT are shown. The mRNA for each gene shown were first normalized to mRNA of endogenous control gene ALAS1, the levels of which
do not significantly change throughout the time course (data not shown). (E) As in (D), but for genes known to be repressed by EBNA3C (COBLL1,
ADAM28, ADAMDEC1 and CXCR5). For all QPCR, error bars represent standard deviations calculated from triplicates for each sample.
genes in the microarray studies. Therefore, this change in
chromatin character might be brought about by the process
of B cell activation itself, facilitating EBNA3 binding to dis-
tal sites––the EBNA3s then exerting their influence follow-
ing chromatin looping to other genes and/or regulatory el-
ements.
Chromatin looping seems to be a very important me-
diator of EBNA3 function, as has been shown previously
for individual genes (22,27). It has been assumed that this
effect is genome-wide because the EBNA3s associate very
frequently with enhancer regions (24,27–29). To explore
the role of chromatin looping in EBNA3 function glob-
ally, we used the chromatin contact domains discovered for
LCL GM12878 recently (31), in order to relate EBNA3
peaks to known, robustly regulated genes by each EBNA3
(see results). Although this sort of analysis could be ob-
fuscated by either too stringent or too lax cut-off criteria
or technical limitations, in this case the statistical signifi-
cance of peak enrichment in contact domains with EBNA3-
regulated genes was obvious and strong (Figure 3C). There
are significantly more peaks in contact domains with regu-
lated genes than in domains without the regulated genes we
considered. This was true for all categories of genes, apart
from EBNA3B-activated genes, indicating that EBNA3B
might not up-regulate genes by direct contact with their
genomic location. There are two, non-mutually exclusive,
possibilities for EBNA3B-mediated activation without di-
rect contact with activated genes. Either EBNA3B acti-
vation of genes results from EBNA3B directly repressing
other genes, or EBNA3B disrupts chromatin looping that
would have caused repression, hadEBNA3Bnot been there.
Indeed, prevention of looping by the EBNA3s has been
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shown directly (27) and an element of this could be present
for all classes of EBNA3-regulated genes, especially in the
EBNA3A-activated genes, where the enrichment for peaks
is significant, but not as pronounced as for others (Figure
3C). The conclusions of this analysis are reinforced by sim-
ilar trends observed when using random ‘peaks’, although
here a similar statistical analysis would not be appropriate.
This is because more than one real peaks can be observed
within a single domain. This is scored as one positive with
real peaks, but could produce more positive hits with ran-
dom peaks [independence of outcome violated (47)]. More
significantly, the conclusion that EBNA3B-mediated acti-
vation is indirect is supported by the observations made
when considering contact domains with more than one reg-
ulated genes, with almost no such EBNA3B up-regulated
genes observed (Table 1).
Contact domains with more than one regulated gene
revealed another important aspect of EBNA3 regulation,
namely that regulated genes in contact with the same peaks
are regulated in the same direction, either all being activated
or all being repressed. This implies that factors determining
the direction of regulation reside at the peak region and are
not dependent on the cis context of the gene proximal re-
gions, which might only be relevant in determining whether
looping occurs, but not for its functional outcome.
ChIP-seq data also highlighted the CBF component
RUNX3 as the most commonly co-localising factor with
the EBNA3s and an obvious candidate for further study.
This seemed particularly germane since infection of B cells
with EBV changes the composition of CBF, from RUNX1-
CBF heterodimers to RUNX3-CBF heterodimers, by
inducing RUNX3 and suppressing RUNX1 (55). EBNA2
(and probably EBNA3B and EBNA3C) plays a direct role
in this effect (55–57) and RUNX3 subsequently mediates
the repression of RUNX1 (56,66–69). The composition
of CBF appears to be associated with B cell differentia-
tion stages (69–71). The switch from RUNX1 to RUNX3
is important for LCL proliferation, since siRNA deple-
tion of RUNX3 (leading to increase of RUNX1) or ex-
ogenous expression of RUNX1 results in impairment of
LCL outgrowth (56,67). We sought to test the hypothe-
sis that RUNX3-containing CBF, in addition to repress-
ing growth-restricting RUNX1, is also directly involved in
EBNA3 functions.
Co-immunoprecipitation of EBNA3A, EBNA3B and
EBNA3C with RUNX3 partner CBF supported this hy-
pothesis. There is a stronger physical association with
EBNA3B than with EBNA3C (or EBNA3A––which co-
precipitates very weakly under the same conditions) (Figure
5). Although we have shown that EBNA3B and EBNA3C
can co-immunoprecipitate independently of each other
(Supplementary Figure S5), it remains unclear why co-
localization studies suggest the reverse order of associa-
tion with CBF. A possible explanation is that one EBNA3
can recruit one or both of the others to some sites since
there is evidence of the EBNA3s physically interacting with
each other in solution (42). Alternatively, or in addition,
there could be combinations of multiple factors targeting
the EBNA3s to regions of the genome. The important ob-
servation is that for the first timewe also show that depletion
of RUNX3 or its co-factor CBF (knockdown of which
also reduces levels of RUNX3) leads to a reduced recruit-
ment of EBNA3A, EBNA3B and EBNA3C (Figure 6).
However, it also seems that the relationship between
EBNA3C and CBF during recruitment to chromatin is
reciprocal––EBNA3C also facilitates robust stabilization or
increased binding affinity of RUNX3 and CBF onto chro-
matin (Figure 7). This is reminiscent of the relationship be-
tween EBNA3C and EBNA2 with RBPJ (26,72), a factor
long known to interact with EBNA2 and all EBNA3s (re-
viewed in 5) and thought to play a role in their recruit-
ment to chromatin––but probably only at a subset of bind-
ing sites (29,72). A question of cause and effect arises. None
of the EBNA3s appear to have a DNA binding domain
(21 and our unpublished data), so they must require DNA
binding factors to associate with chromatin specifically and
efficiently. A combination of factors is likely to decide
EBNA3 recruitment. The ChIP-seq data on RUNX3 and
the EBNA3s suggest that there are thousands of RUNX3
binding sites with no evidence of EBNA3 binding, consis-
tent with a requirement for additional factors. There must
also be a role for other cis elements making regions of the
genome more susceptible to EBNA3 binding. These are
likely to be where chromatin is open or opens as a conse-
quence of B cell activation, thus being available for binding
of multimeric complexes containing EBNA3s and then be-
ing stabilized as a result of combinatorial binding.
Irrespective of the precise sequence of events or variety
of factors involved, CBF is clearly very important. The high
degree of co-localization, the co-immunoprecipitation and
the requirement for CBF in efficient targeting of EBNA3B
and EBNA3C to chromatin are consistent with this. More-
over, it could be significant that CBF has also been shown to
directly recruit polycomb repressive complex 1 (PRC1) sub-
unit BMI1 (73), a factor also shown to affect EBNA3 gene
regulation (42). Finally, we show (Figure 8) that CBF is re-
quired for both activation and repression of host genes by
EBNA3C. These data definitively establish CBF as a central
component of the complex gene regulatory network that
links EBNA2, the EBNA3 family and multiple host genes
during EBV latency and B cell transformation.
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